These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27776965)

  • 1. Experience with botulinum toxin in chronic migraine.
    Castrillo Sanz A; Morollón Sánchez-Mateos N; Simonet Hernández C; Fernández Rodríguez B; Cerdán Santacruz D; Mendoza Rodríguez A; Rodríguez Sanz MF; Tabernero García C; Guerrero Becerra P; Ferrero Ros M; Duate García-Luis J
    Neurologia (Engl Ed); 2018 Oct; 33(8):499-504. PubMed ID: 27776965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC; Fernández-García JM; Aranzábal-Alustiza I; Castillo-Calvo B; Iriondo-Etxenagusia I; Rodríguez-Antigüedad A
    Rev Neurol; 2012 Oct; 55(7):385-91. PubMed ID: 23011856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
    J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence to onabotulinumtoxinA to prevent chronic migraine: results from 11 years of patient data from a tertiary headache center.
    Moskatel LS; Graber-Naidich A; He Z; Zhang N
    Pain Med; 2024 Aug; 25(8):487-492. PubMed ID: 38518091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
    Palma JA; Irimia P; Fernandez-Torron R; Ortega-Cubero S; Riverol M; Luquin MR; Martinez-Vila E
    Rev Neurol; 2012 Jun; 54(12):705-11. PubMed ID: 22673946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
    d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
    J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [OnabotulinumtoxinA in chronic migraine: from the theory of clinical trials to clinical practice].
    Leira R
    Rev Neurol; 2014 Mar; 58 Suppl 2():S3-11. PubMed ID: 24687883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE; Silberstein S
    Drugs; 2018 Apr; 78(5):589-600. PubMed ID: 29532439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
    Quintas S; García-Azorín D; Heredia P; Talavera B; Gago-Veiga AB; Guerrero ÁL
    Pain Med; 2019 Sep; 20(9):1815-1821. PubMed ID: 30657951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
    Cernuda-Morollón E; Ramón C; Larrosa D; Alvarez R; Riesco N; Pascual J
    Cephalalgia; 2015 Sep; 35(10):864-8. PubMed ID: 25431141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
    Aydinlar EI; Dikmen PY; Kosak S; Kocaman AS
    J Headache Pain; 2017 Dec; 18(1):23. PubMed ID: 28213829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine].
    Pagola I; Esteve-Belloch P; Palma JA; Luquin MR; Riverol M; Martinez-Vila E; Irimia P
    Rev Neurol; 2014 Mar; 58(6):241-6. PubMed ID: 24610690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
    Gonzalez-Martinez A; Rodríguez Vázquez E; de la Red Gallego H; García-Azorín D; Gallego de La Sacristana M; Guerrero Peral ÁL; Gago-Veiga AB
    Headache; 2020 Jan; 60(1):153-161. PubMed ID: 31691958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What is the optimal dose for the prophylactic treatment of chronic migraine patients?].
    Irimia P; Esteve-Belloch P; Murie-Fernandez M; Martinez-Vila E
    Rev Neurol; 2014 Mar; 58 Suppl 2():S13-9. PubMed ID: 24687880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.